Sign in
Molecular BiologyProceedings of the National Academy of Sciences
Peer-reviewed journal article

MicroRNA-34a suppresses KLF2 to promote pathological angiogenesis through the CXCR4/CXCL12 pathway in age-related macular degeneration

Jason J. ColasantiiD, Andrea C. SantefordiD, Joseph B. LiniD, Ryo TeraoiD, Tae Jun LeeiD, Rajendra S. ApteiD

Abstract

Age-related macular degeneration (AMD), characterized by pathologic choroidal neovascularization (CNV), is a leading cause of vision loss in the elderly. Vascular endothelial growth factor A (VEGFa) antagonists can prevent acute vision loss, but high treatment burden and loss of efficacy with chronic therapy highlight the need to explore alternative mechanisms. Recently, microRNA-34a (miR-34a) has emerged as a key regulator in aging and age-related diseases, but its role in neovascular AMD is unclear. In an injury-induced murine CNV model, we discovered miR-34a promoted pathological angiogenesis, without altering expression of Vegfa or its receptor Kdr, the canonical regulators of CNV. Mechanistically, miR-34a directly targets and inhibits the transcription factor KLF2 thereby upregulating the pro-angiogenic factors CXCR4 and CXCL12. Finally, we show miR-34a exacerbates CNV in aged mice and is expressed in CNV lesions excised from wet AMD patients. These findings establish a causal link between the age-related miR-34a and neovascularization in AMD. TeaserIdentification of a molecular mechanism involved in the pathogenesis of a prevalent and debilitating age-related ocular disease.

PDFDOI

02 /Specification & Classification

Click any tag to browse matching papers

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISHarris '26Wolf '22Chen '25Kopacz '25Yang '19Huang '19
72% semantic matchBiochemistry
Chanel Harris, Mohammed A Nisar, Ankit Seth+6 more·bioRxiv·Oct 23, 2026